Postoperative Adjuvant Systemic Therapy in Completely Resected Non–Small-Cell Lung Cancer: A Systematic Review

Clinical Lung Cancer

Volumn 18, Issue 3, 2017, Pages 259-273.e8

  Bradbury, Penelope ^a   Sivajohanathan, Duvaraga ^b   Chan, Adrien ^c   Kulkarni, Swati ^d   Ung, Yee ^e   Ellis, Peter M ^f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

^d Centre Regional De Cancerologie De Windsor   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Chemotherapy; Clinical trials; Immunotherapy; NSCLC; Targeted therapy

Indexed keywords

BETA TUBULIN; BEVACIZUMAB; BIOLOGICAL MARKER; CISPLATIN; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; K RAS PROTEIN; MICRORNA; MUCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN P16; PROTEIN P27;

ADJUVANT THERAPY; ADVERSE OUTCOME; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DISEASE FREE SURVIVAL; DYSPNEA; EXCISION REPAIR; FATIGUE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INFECTION; LUNG RESECTION; LYMPHOCYTIC INFILTRATION; META ANALYSIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTOPERATIVE CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; TUMOR VOLUME; VOMITING; ADJUVANT CHEMOTHERAPY; CELL DEATH; LUNG TUMOR; MORTALITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; SURVIVAL ANALYSIS;

CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; PNEUMONECTOMY; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 85011362895     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.07.002     Document Type: Review

References (87)

1. 1 Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2015. 2015, Canadian Cancer Society, Toronto, ON.
2. 2 Arriagada, R., Bergman, B., Dunant, A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004), 351–360.
3. 3 Douillard, J.Y., Rosell, R., De Lena, M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006), 719–727.
4. 4 Strauss, G.M., Herndon, J.E. 2nd, Maddaus, M.A., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26 (2008), 5043–5051.
5. 5 Winton, T., Livingston, R., Johnson, D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005), 2589–2597.
6. 6 Butts, C.A., Ding, K., Seymour, L., et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 28 (2010), 29–34.
7. 7 Alam, N., Darling, G., Evans, W.K., Mackay, J.A., Shepherd, F.A., Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based C. Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Crit Rev Oncol Hematol 58 (2006), 146–155.
8. 8 Alam, N., Darling, G., Shepherd, F., Mackay, J., Evans, W., Postoperative chemotherapy in non-small- cell lung cancer: a systematic review. Ann Thorac Surg 81 (2006), 1926–1936.
9. 9 Alam, N., Shepherd, F.A., Darling, G., Mackay, J.A., Ung, Y., Evans, W.K., Postoperative adjuvant chemotherapy, with or without radiotherapy, in completely resected non-small-cell lung cancer: a clinical practice guideline. Program in Evidence-Based Care Guideline No. 7-1-2. 2006, Cancer Care Ontario, Toronto, Ontario, Canada.
10. 10 Pisters, K.M., Evans, W.K., Azzoli, C.G., et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25 (2007), 5506–5518.
11. 11 Okawara, G., Ung, Y.C., Markman, B.R., Mackay, J.A., Evans, W.K., Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based C. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 44 (2004), 1–11.
12. 12 Bradbury, P., Sivajohanathan, D., Chan, A., Kulkarni, S., Ung, Y., Ellis, P., Postoperative adjuvant systemic therapy in completely resected non-small cell lung cancer. 2016, Cancer Care Ontario, Toronto, ON.
13. 13 Shea, B.J., Grimshaw, J.M., Wells, G.A., et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 7, 2007, 10.
14. 14 Guyatt, G., Oxman, A., Akl, E., et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64 (2011), 383–394.
15. 15 Pignon, J.P., Tribodet, H., Scagliotti, G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26 (2008), 3552–3559.
16. 16 Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375 (2010), 1267–1277.
17. 17 Chen, Y.Y., Wang, L.W., Wang, S.Y., et al. Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer. Onco Targets Ther 8 (2015), 2033–2043.
18. 18 Shen, J., Yang, C., Jiang, L., et al. Adjuvant chemotherapy for the completely resected stage IB nonsmall cell lung cancer. Medicine (United States), 94, 2015, e903.
19. 19 Seymour, L.K., Le Teuff, G., Tsao, M., et al. Prognostic and predictive biomarkers for ACT (adjuvant chemotherapy) in resected non-small cell lung cancer: LACE-BIO. Ann Oncol 25 (2014), iv58–iv84.
20. 20 Bezjak, A., Lee, C., Ding, K., et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Results from a randomized trial, JBR.10. J Clin Oncol 26 (2008), 5052–5059.
21. 21 Tsao, M.S., Sakurada, A., Ding, K., et al. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 6 (2011), 139–147.
22. 22 Bennouna, J., Senellart, H., Hiret, S., Vaissiere, N., Douillard, J.Y., Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. Lung Cancer 74 (2011), 30–34.
23. 23 Strauss, G., Herndon, J., Maddaus, M., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol, 22, 2004, 7019.
24. 24 Strauss, G., Herndon, J., Maddaus, M., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol, 24(suppl), 2006, 7007.
25. 25 Capelletti, M., Wang, X., Gu, L., et al. Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. J Clin Oncol, 28(suppl), 2010, 15s.
26. 26 Graziano, S., Paris, E., Ma, X., et al. Lace-bio pooled analysis of the prognostic and predictive value of p53 mutations and expression by immunohistochemistry (IHC) in patients with resected non-small cell lung cancer (NSCLC). Ann Oncol, 21, 2010, viii130.
27. 27 Strauss, G., Wang, X., Maddaus, M., et al. Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633. J Clin Oncol, 29(suppl), 2011 abstract 7015.
28. 28 Arriagada, R., Dunant, A., Pignon, J.P., et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 28 (2010), 35–42.
29. 29 Voortman, J., Goto, A., Mendiboure, J., et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70 (2010), 8288–8298.
30. 30 Pierceall, W.E., Olaussen, K.A., Rousseau, V., et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 23 (2012), 2245–2252.
31. 31 Olaussen, K.A., Adam, J., Vanhecke, E., et al. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer 80 (2013), 216–222.
32. 32 Ma, X., Rousseau, V., Sun, H., et al. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. Mol Oncol 8 (2014), 555–564.
33. 33 Wang, J., Liu, F., Huang, D.X., Jiang, B., Post-operative treatment with cisplatin and vinorelbine in chinese patients with non-small cell lung cancer: a clinical prospective analysis of 451 patients. Asian Pac J Cancer Prev 13 (2012), 4505–4510.
34. 34 Felip, E., Rosell, R., Maestre, J.A., et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 28 (2010), 3138–3145.
35. 35 Ou, W., Sun, H.B., Ye, X., et al. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer. J Thorac Oncol 5 (2010), 1033–1041.
36. 36 Wang, S.Y., Sun, H., Ou, W., Fang, Q., Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small cell lung cancer. J Clin Oncol, 30(suppl 1), 2012.
37. 37 Wakelee, H.A., Dahlberg, S.E., Keller, S.M., et al. Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): results of E1505. J Thorac Oncol, 10, 2015, S796.
38. 38 Goss, G.D., O'Callaghan, C., Lorimer, I., et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 31 (2013), 3320–3326.
39. 39 Kelly, K., Altorki, N.K., Eberhardt, W.E., et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol 33 (2015), 4007–4014.
40. 40 Therasse, P., Vansteenkiste, J.F., Zielinski, M., et al. MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC. J Clin Oncol, 29(suppl), 2011, TPS210.
41. 41 Vansteenkiste, J., Cho, B., Vanakesa, T., et al. MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer. Ann Oncol 25 (2014), iv409–iv416.
42. 42 Kimura, H., Matsui, Y., Ishikawa, A., Nakajima, T., Yoshino, M., Sakairi, Y., Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. Cancer Immunol Immunother 64 (2015), 51–59.
43. 43 Khranovska, N., Ganul, V., Grinevich, Y., et al. Clinical and immunological effectiveness of dendritic cell immunotherapy in lung cancer patients: 5-years follow-up period. J Thorac Oncol, 1, 2012, S37.
44. 44 Khranovska, N., Skachkova, O., Ganul, A., et al. Results from phase III trial of dendritic cell based vaccine immunotherapy in patients with-IIIA stage non-small-cell lung cancer. J Thorac Oncol, 8, 2013, S910.
45. 45 Khranovska, N., Skachkova, O., Ganul, A., et al. Immunological biomarkers as surrogates for clinical response for dendritic cells vaccine therapy for non-small cell lung cancer and renal cell carcinoma. Eur J Cancer, 49, 2013, S145.
46. 46 Douillard, J.Y., Tribodet, H., Aubert, D., et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 5 (2010), 220–228.
47. 47 Cuffe, S., Bourredjem, A., Graziano, S., et al. A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. J Thorac Oncol 7 (2012), 963–972.
48. 48 Brambilla, E., Tsao, M., Paris, E., et al. Lace-bio: results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration. Ann Oncol, 21, 2010, viii130.
49. 49 Brambilla, E., Marguet, S., Le Teuff, G., et al. Prognostic and predictive value of a new IASLC/ATS/ERS lung adenocarcinoma classification in a pooled analysis of four adjuvant chemotherapy trials: a lace-bio study. J Thorac Oncol, 8, 2013, S201.
50. 50 Tsao, M.S., Marguet, S., Le Teuff, G., et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol 33 (2015), 3439–3446.
51. 51 Soria, J.C., Brambilla, E., Le Teuff, G., et al. A pooled analysis to evaluate the prognosis and predictive value of EGFR mutation on survival in patients with KRAS wild-type lung adenocarcinoma. J Thorac Oncol, 2, 2011, S617.
52. 52 Tsao, M., Hainaut, P., Bourredjem, A., et al. Lace-bio pooled analysis of the prognostic and predictive value of kras mutation in completely resected non-small cell lung cancer (NSCLC). Ann Oncol, 21, 2010, viii63.
53. 53 Shepherd, F.A., Domerg, C., Hainaut, P., et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 31 (2013), 2173–2181.
54. 54 Janne, P., Shepherd, F., Domerg, C., et al. Prognostic and predictive values of KRAS in EGFR-based subgroups and combined with p53 in completely resected non-small cell lung cancer (NSCLC): a lace-bio study. Ann Oncol, 23, 2012, ix74.
55. 55 Hainaut, P., Ma, X., Lacas, B., et al. Lace-bio pooled analysis of the prognostic and predictive value of TP53 mutations in completely resected non small cell lung cancer (NSCLC). Ann Oncol, 23, 2012, ix389.
56. 56 Friboulet, L., Olaussen, K.A., Pignon, J.P., et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368 (2013), 1101–1110.
57. 57 Reiman, T., Lai, R., Veillard, A.S., et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 23 (2012), 86–93.
58. 58 Graziano, S.L., Gu, L., Wang, X., et al. Prognostic significance of mucin and P53 expression in stage ib non-small cell lung cancer: A laboratory companion study to CALGB 9633. J Thorac Oncol 5 (2010), 810–817.
59. 59 Pirker, R., Rousseau, V., Paris, E., et al. LACE-bio: cross-validation and pooled analyses of the putative prognostic/predictive biomarkers p27, p16 and cyclin E in IALT, ANITA, JBR10 and CALGB 9633. J Thorac Oncol, 5, 2010, S503.
60. 60 Brambilla, E., Bourredjem, A., Lantuejoul, S., et al. Bax expression as a predictive marker of survival benefit in non-small cell lung carcinoma treated by adjuvant cisplatin-based chemotherapy. J Thorac Oncol 5 (2010), S503–S504.
61. 61 Gandara, D.R., Kawaguchi, T., Crowley, J., et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 27 (2009), 3540–3546.
62. 62 Dautzenberg, B., Chastang, C., Arriagada, R., et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma: a randomized trial of 267 patients. Cancer 76 (1995), 779–786.
63. 63 Endo, C., Saito, Y., Iwanami, H., et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 40 (2003), 181–186.
64. 64 Feld, R., Rubinstein, L., Thomas, P., et al. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. J Natl Cancer Inst 85 (1993), 299–306.
65. 65 Figlin, R., Piantodosi, S., A phase 3 randomized trial of immediate combination chemotherapy vs delayed combination chemotherapy in patients with completely resected stage II and III non-small cell carcinoma of the lung. Chest 106 (1994), 310S–312S.
66. 66 Imaizumi, M., Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer 49 (2005), 85–94.
67. 67 Kato, H., Ichinose, Y., Hata, E., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004), 1713–1721.
68. 68 Keller, S.M., Adak, S., Wagner, H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343 (2000), 1217–1222.
69. 69 Kimura, H., Yamaguchi, Y., Fujisawa, T., Baba, M., Shiba, M., A randomized controlled study of postoperative adjuvant chemoimmunotherapy of resected non-small cell lung cancer with IL2 and LAK cells. Lung Cancer, 7(suppl), 1991, 133.
70. 70 Lad, T., Rubinstein, L., Sadeghi, A., The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 6 (1988), 9–17.
71. 71 Mineo, T., Ambrogi, V., Corsaro, V., Roselli, M., Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg 20 (2001), 378–384.
72. 72 Nakagawa, K., Tada, H., Akashi, A., et al. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. Br J Cancer 95 (2006), 817–821.
73. 73 Nakagawa, M., Tanaka, F., Ohta, M., et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG) - The 4th study. Ann Oncol 16 (2005), 75–80.
74. 74 Niiranen, A., Niitamo-Korhonen, S., Kouri, M., Assendelft, A., Mattson, K., Pyrhonen, S., Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol 10 (1992), 1927–1932.
75. 75 Ohta, M., Tsuchiya, R., Shimoyama, M., et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer: results of a randomized prospective study. J Thorac Cardiovasc Surg 106 (1993), 703–708.
76. 76 Park, J.H., Lee, C.T., Lee, H.W., Baek, H.J., Zo, J.I., Shim, Y.M., Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer. Eur J Cardiothorac Surg 27 (2005), 1086–1091.
77. 77 Park, J., Postoperative adjuvant therapy for stage IIIA non-small cell lung cancer. J Thorac Oncol, 2(suppl), 2007, S651.
78. 78 Pisters, K.M., Kris, M.G., Gralla, R.J., et al. Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer. J Surg Oncol 56 (1994), 236–241.
79. 79 Sawamura, K., Mori, T., Doi, O., et al. A prospective randomized controlled study of the postoperative adjuvant therapy for non-small cell lung cancer. Lung Cancer, 4, 1988, A166.
80. 80 Scagliotti, G., Novello, S., Adjuvant chemotherapy after complete resection for early stage NSCLC. Lung Cancer 42 (2003), S47–S51.
81. 81 Study Group for Adjuvant Chemotherapy for Lung Cancer. A randomzed controlled trial of post-operative adjuvant therapy for non-small cell lung cancer. Hai-gan 1992 (1992), 481–486.
82. 82 Study Group for Adjuvant Chemotherapy for Lung Cancer. A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur J Surg Oncol 21 (1995), 69–77.
83. 83 Tada, H., Tsuchiya, R., Ichinose, Y., et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 43 (2004), 167–173.
84. 84 Wada, H., Hitomi, S., Teramatsu, T., Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 14 (1996), 1048–1054.
85. 85 Wada, H., Miyahara, R., Tanaka, F., Hitomi, S., Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 15 (1999), 438–443.
86. 86 Waller, D., Peake, M., Stephens, R., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26 (2004), 173–182.
87. 87 Xu, G., Rong, T., Lin, P., Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: a randomized study. Zhonghua Zhong Liu Za Zhi 20 (1998), 228–230.